Sage Therapeutics Investors Urged to Act Before Deadline
Important Notice for Sage Therapeutics Investors
The Gross Law Firm is reaching out to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE), highlighting a significant class action lawsuit that requires their attention.
Class Period and Shareholder Engagement
Shareholders who purchased shares of SAGE during the designated class period are encouraged to connect with the legal team about the potential for lead plaintiff appointment. It's important to note that participating as a lead plaintiff is not a requirement for financial recovery.
Contacting the Firm
Shareholders interested in joining the lawsuit are invited to contact the law firm directly. This enables them to stay informed about the ongoing developments in their case.
Details of the Class Action
CLASS PERIOD: The time frame spans from April 12, 2021, to July 23, 2024.
ALLEGATIONS: The lawsuit alleges that during this period, the issuing of misleading statements regarding Sage's products has affected investor decisions. Specific allegations include:
- Zuranolone was purportedly less effective in treating Major Depressive Disorder than communicated to investors.
- The FDA's likelihood of approving the Zuranolone NDA in its current form was overstated.
- SAGE-718's effectiveness in treating Mild Cognitive Impairment related to Parkinson’s Disease was inaccurately presented.
- Claims regarding SAGE-324's effectiveness as a treatment for essential tremor were misleading.
As a result of these alleged misrepresentations, investors faced significant concerns and uncertainties regarding SAGE's operational and financial health.
Critical Deadlines for Participation
DEADLINE: The last date for shareholders to register their interest in participating in the class action is October 28, 2024. Immediate registration is advised to ensure eligibility.
Next Steps for Interested Shareholders
When a shareholder registers their investment made during the specified time frame, they'll gain access to portfolio monitoring tools that will keep them updated about the progression of their case. Additionally, there is no fee for participating in this lawsuit, making it accessible for all eligible investors.
About The Gross Law Firm
The Gross Law Firm is well-recognized in the field of class action litigation, striving to safeguard the rights of investors affected by unethical practices and misinformation. Their commitment is to uphold accountability among corporations, ensuring they engage in responsible business practices that contribute positively to shareholder trust and the broader community.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the importance of the upcoming deadline?
The deadline of October 28, 2024, is critical for shareholders to register their interest and potentially participate in the class action lawsuit.
Who can join the class action lawsuit?
Any shareholder who purchased shares of Sage Therapeutics Inc. during the class period (April 12, 2021, to July 23, 2024) can register to participate.
What are the allegations against Sage Therapeutics?
The allegations include misleading claims regarding the effectiveness and regulatory approval chances of SAGE products, significantly Zuranolone, SAGE-718, and SAGE-324.
Is there a cost to participate in the lawsuit?
No, there is no cost or obligation to participate in the class action for eligible shareholders.
How will I be informed about the case's status?
Registered shareholders will receive updates through a portfolio monitoring service provided by the Gross Law Firm.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Facilitron Partners with Schools to Elevate Facility Management
- Venture Capitalist Critiques Gensler's Crypto Regulations Impact
- Real Estate Stocks Under Pressure: KRC and DEI Show Warning Signs
- Exploring Promising Stocks in the Cryptocurrency Landscape
- Yum China Sees Stock Recovery: Navigating Challenges Ahead
- Micron Technology's Latest Innovations Sending Stock Soaring
- Lucid Capital Offers Target Price For Gladstone Land Shares
- CFRA Affirms Buy Rating for Rio Tinto with Target at GBP56.00
- Turning $1,000 into $2,800 with Fluor: A 5-Year Journey
- Hawkins Inc. Achieves Record Stock Milestone at $134.79
Recent Articles
- Investors Take Action: Methode Electronics Class Action Update
- Endava plc Investors Alerted on Class Action Lawsuit Updates
- Iris Energy Limited's Shareholders Targeted in Class Action
- Class Action Alert: GitLab Inc. (GTLB) Shareholders Update
- Class Action Alert for Elanco Animal Health Investors
- Join the Class Action Against Verve Therapeutics Before the Deadline
- Heimar hf. Completes Successful Share Buyback Program
- Investigation Into Alleged Misconduct at AMMO, Inc. Unfolds
- COURTOIS SA Reports Impressive Q3 Revenue Growth Metrics
- Investigation Launched Into Endava: What Investors Must Know
- Rhode Island's Tourism Campaign Shines with Magellan Awards
- SiriusXM Holdings Stock Gains: Insights and Investing Tips
- Sparx Hockey Partners to Elevate Skate Sharpening in Sweden
- Understanding the P/E Ratio: Insights on Equifax's Performance
- Vaco Recognized Among America’s Top Workplaces for 2025
- Federal Government Initiates Housing Development on Public Land
- Empowering Investors: Mastering Retirement Income Strategies
- Investors Have a Chance to Join Terran Orbital Lawsuit Now
- Builders Thrives as a Top Employer for 2024 Recognition
- Impact of Upcoming US Presidential Election on Tech Investments
- Freight Farms Welcomes New CEO Brad Griffith to Lead Growth
- EVERSANA Celebrates Global Workplace Excellence for 2024
- Introducing SECUR: A New Era in Medicare Advantage Care
- Innovative AI Applications for Corporate Treasury Insights
- Steve Aoki Invests in Neuro Gum, Pioneering Mental Clarity
- Investigating GitLab: What Investors Need to Know Now
- Mesabi Trust Achieves New Milestone with Stock Surge
- Oppenheimer Adjusts Citigroup's Outlook Amid Mixed Results
- Alibaba and Baidu Invest in Autonomous Driving IPO Success
- Axogen Inc. Achieves New Heights with Stock Surge to $15.12
- MasTec's Bright Future: Analysts See Growth in AI and Renewables
- Longboard Pharmaceuticals Acquisition: What Investors Need to Know
- CPS Technologies Transitions to New Accounting Firm, Eyes Growth
- UBS Lowers Shanghai Airport Target Amid Economic Pressures
- Investors Encouraged to Join DexCom Class Action Lawsuit
- Canaccord Genuity Raises Price Target for Imdex Shares
- Mill City Ventures Announces $2 Million Stock Buyback Plan
- Lithium Americas and GM Focus on Major Investment in Battery Supply
- Stifel's Hold Rating on Air Canada Amid Growth Strategies
- Matador Resources Undergoes Key Adjustments, Future Looks Bright
- A Deep Dive Into Discover Financial's Long-Term Growth
- Unlocking Wealth: How PulteGroup Stock Became a Goldmine
- Investigation on Paragon 28: What Investors Need to Know
- Bayen Group's Innovative Solutions Enrich Defense Contracts
- GSK's Groundbreaking Oral Antibiotic Targets Urinary Infections
- Investigation Launched for New Fortress Energy Investors
- Investigation Underway for Investors of Bumble Inc.
- Healthcare Facility Management Market Soars to $870 Billion
- Political Turbulence as France's Budget Faces Backlash
- Investors Eye Bullish Moves in Robinhood Markets Options